Targeting von Willebrand Factor in Ischaemic Stroke: Focus on Clinical Evidence

Nina Buchtele, Michael Schwameis, James C Gilbert, Christian Schörgenhofer, Bernd Jilma, Nina Buchtele, Michael Schwameis, James C Gilbert, Christian Schörgenhofer, Bernd Jilma

Abstract

Despite great efforts in stroke research, disability and recurrence rates in ischaemic stroke remain unacceptably high. To address this issue, one potential target for novel therapeutics is the glycoprotein von Willebrand factor (vWF), which increases in thrombogenicity especially under high shear rates as it bridges between vascular sub-endothelial collagen and platelets. The rationale for vWF as a potential target in stroke comes from four bodies of evidence. (1) Animal models which recapitulate the pathogenesis of stroke and validate the concept of targeting vWF for stroke prevention and the use of the vWF cleavage enzyme ADAMTS13 in acute stroke treatment. (2) Extensive epidemiologic data establishing the prognostic role of vWF in the clinical setting showing that high vWF levels are associated with an increased risk of first stroke, stroke recurrence or stroke-associated mortality. As such, vWF levels may be a suitable marker for further risk stratification to potentially fine-tune current risk prediction models which are mainly based on clinical and imaging data. (3) Genetic studies showing an association between vWF levels and stroke risk on genomic levels. Finally, (4) studies of patients with primary disorders of excess or deficiency of function in the vWF axis (e.g. thrombotic thrombocytopenic purpura and von Willebrand disease, respectively) which demonstrate the crucial role of vWF in atherothrombosis. Therapeutic inhibition of VWF by novel agents appears particularly promising for secondary prevention of stroke recurrence in specific sub-groups of patients such as those suffering from large artery atherosclerosis, as designated according to the TOAST classification.

Conflict of interest statement

J.G. is the founder of Band Therapeutics, a ‘virtual’ biotech company that was established to discover and develop novel biotherapeutics targeting von Willebrand factor. Other authors declare no conflict of interest.

Schattauer GmbH Stuttgart.

Figures

Fig. 1
Fig. 1
Scheme of von Willebrand factor (vWF) under high shear rates. Legend: Different mechanisms of actions of investigational von Willebrand factor inhibitors are described, i.e., GPIbα-vWF, ultra-large vWF multimers (recombinant ADAMTS13) and collagen-vWF. GP, glycoprotein.

References

    1. Lozano R, Naghavi M, Foreman Ket al.Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 2012380(9859):2095–2128.
    1. Benjamin E J, Blaha M J, Chiuve S E et al.Heart Disease and Stroke Statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146–e603.
    1. Tsai C F, Thomas B, Sudlow C L. Epidemiology of stroke and its subtypes in Chinese vs white populations: a systematic review. Neurology. 2013;81(03):264–272.
    1. Heuschmann P U, Di Carlo A, Bejot Y et al.Incidence of stroke in Europe at the beginning of the 21st century. Stroke. 2009;40(05):1557–1563.
    1. Feigin V L, Forouzanfar M H, Krishnamurthi Ret al.Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010 Lancet 2014383(9913):245–254.
    1. Mozaffarian D, Benjamin E J, Go A S et al.Executive summary: Heart Disease and Stroke Statistics--2016 update: a report from the American Heart Association. Circulation. 2016;133(04):447–454.
    1. Di Carlo A. Human and economic burden of stroke. Age Ageing. 2009;38(01):4–5.
    1. Adams H P, Jr, Effron M B, Torner J et al.Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II) Stroke. 2008;39(01):87–99.
    1. Ciccone A, Motto C, Abraha I, Cozzolino F, Santilli I. Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke. Cochrane Database Syst Rev. 2014;(03):CD005208.
    1. Montalescot G, Wiviott S D, Braunwald Eet al.Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial Lancet 2009373(9665):723–731.
    1. Morrow D A, Alberts M J, Mohr J P et al.Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke. 2013;44(03):691–698.
    1. Denorme F, De Meyer S F. The VWF-GPIb axis in ischaemic stroke: lessons from animal models. Thromb Haemost. 2016;116(04):597–604.
    1. Adams H P, Jr, Bendixen B H, Kappelle L J et al.Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(01):35–41.
    1. Petty G W, Brown R D, Jr, Whisnant J P, Sicks J D, O'Fallon W M, Wiebers D O. Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence. Stroke. 2000;31(05):1062–1068.
    1. Koppelman S J, van Hoeij M, Vink T et al.Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein C. Blood. 1996;87(06):2292–2300.
    1. Hannah M J, Williams R, Kaur J, Hewlett L J, Cutler D F. Biogenesis of Weibel-Palade bodies. Semin Cell Dev Biol. 2002;13(04):313–324.
    1. Schoergenhofer C, Matzneller P, Mußbacher M et al.Colistin dampens fibrinolysis and endothelial activation during endotoxaemia. A randomised, double blind trial. Thromb Haemost. 2017;117(09):1714–1721.
    1. Jilma B, Pernerstorfer T, Dirnberger E et al.Effects of histamine and nitric oxide synthase inhibition on plasma levels of von Willebrand factor antigen. J Lab Clin Med. 1998;131(02):151–156.
    1. Siller-Matula J M, Miller I, Gemeiner M et al.Continuous thrombin infusion leads to a bleeding phenotype in sheep. Thromb Res. 2012;130(02):226–236.
    1. Derhaschnig U, Pachinger C, Schweeger-Exeli I, Marsik C, Jilma B. Blockade of GPIIb/IIIa by eptifibatide and tirofiban does not alter tissue factor induced thrombin generation in human endotoxemia. Thromb Haemost. 2003;90(06):1054–1060.
    1. Reiter R A, Mayr F, Blazicek H et al.Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood. 2003;102(13):4594–4599.
    1. Wagner D D, Saffaripour S, Bonfanti R et al.Induction of specific storage organelles by von Willebrand factor propolypeptide. Cell. 1991;64(02):403–413.
    1. Sing C E, Alexander-Katz A. Elongational flow induces the unfolding of von Willebrand factor at physiological flow rates. Biophys J. 2010;98(09):L35–L37.
    1. Marx I, Christophe O D, Lenting P J et al.Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa. Blood. 2008;112(03):603–609.
    1. Petri B, Broermann A, Li H et al.von Willebrand factor promotes leukocyte extravasation. Blood. 2010;116(22):4712–4719.
    1. De Meyer G R, Hoylaerts M F, Kockx M M, Yamamoto H, Herman A G, Bult H. Intimal deposition of functional von Willebrand factor in atherogenesis. Arterioscler Thromb Vasc Biol. 1999;19(10):2524–2534.
    1. Trillo A A, Prichard R W. Early endothelial changes in experimental primate atherosclerosis. Lab Invest. 1979;41(04):294–302.
    1. Möller K, Adolph O, Grünow J et al.Mechanism and functional impact of CD40 ligand-induced von Willebrand factor release from endothelial cells. Thromb Haemost. 2015;113(05):1095–1108.
    1. Nguyen T C, Liu A, Liu L et al.Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis. Haematologica. 2007;92(01):121–124.
    1. Methia N, André P, Denis C V, Economopoulos M, Wagner D D. Localized reduction of atherosclerosis in von Willebrand factor-deficient mice. Blood. 2001;98(05):1424–1428.
    1. van Galen K P, Tuinenburg A, Smeets E M, Schutgens R E. Von Willebrand factor deficiency and atherosclerosis. Blood Rev. 2012;26(05):189–196.
    1. Getz G S, Reardon C A. Animal models of atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32(05):1104–1115.
    1. Bongers T N, de Maat M P, van Goor M L et al.High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke. 2006;37(11):2672–2677.
    1. Folsom A R, Rosamond W D, Shahar E et al.Prospective study of markers of hemostatic function with risk of ischemic stroke. Circulation. 1999;100(07):736–742.
    1. Williams S R, Hsu F C, Keene K L et al.Genetic drivers of von Willebrand factor levels in an ischemic stroke population and association with risk for recurrent stroke. Stroke. 2017;48(06):1444–1450.
    1. Menih M, Križmarić M, Hojs Fabjan T.Clinical role of von Willebrand factor in acute ischemic stroke Wien Klin Wochenschr 2017129(13-14):491–496.
    1. Kraft P, Drechsler C, Gunreben I et al.Von Willebrand factor regulation in patients with acute and chronic cerebrovascular disease: a pilot, case-control study. PLoS One. 2014;9(06):e99851.
    1. Samai A, Monlezun D, Shaban A et al.Von Willebrand factor drives the association between elevated factor VIII and poor outcomes in patients with ischemic stroke. Stroke. 2014;45(09):2789–2791.
    1. Bath P M, Blann A, Smith N, Butterworth R J.Von Willebrand factor, P-selectin and fibrinogen levels in patients with acute ischaemic and haemorrhagic stroke, and their relationship with stroke sub-type and functional outcome Platelets 19989(3-4):155–159.
    1. Carter A M, Catto A J, Mansfield M W, Bamford J M, Grant P J. Predictive variables for mortality after acute ischemic stroke. Stroke. 2007;38(06):1873–1880.
    1. Favaloro E J, Pasalic L, Curnow J. Laboratory tests used to help diagnose von Willebrand disease: an update. Pathology. 2016;48(04):303–318.
    1. Eikenboom J, Federici A B, Dirven R J et al.VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. Blood. 2013;121(12):2336–2339.
    1. Kleinschnitz C, De Meyer S F, Schwarz T et al.Deficiency of von Willebrand factor protects mice from ischemic stroke. Blood. 2009;113(15):3600–3603.
    1. Zhao B Q, Chauhan A K, Canault M et al.von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. Blood. 2009;114(15):3329–3334.
    1. Sanders Y V, Eikenboom J, de Wee E M et al.Reduced prevalence of arterial thrombosis in von Willebrand disease. J Thromb Haemost. 2013;11(05):845–854.
    1. Peyvandi F, Scully M, Kremer Hovinga J A et al.Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2016;374(06):511–522.
    1. Catto A J, Carter A M, Barrett J H, Bamford J, Rice P J, Grant P J. von Willebrand factor and factor VIII: C in acute cerebrovascular disease. Relationship to stroke subtype and mortality. Thromb Haemost. 1997;77(06):1104–1108.
    1. Qizilbash N, Duffy S, Prentice C R, Boothby M, Warlow C. Von Willebrand factor and risk of ischemic stroke. Neurology. 1997;49(06):1552–1556.
    1. Hanson E, Jood K, Karlsson S, Nilsson S, Blomstrand C, Jern C. Plasma levels of von Willebrand factor in the etiologic subtypes of ischemic stroke. J Thromb Haemost. 2011;9(02):275–281.
    1. van Schie M C, DE Maat M P, Dippel D W et al.von Willebrand factor propeptide and the occurrence of a first ischemic stroke. J Thromb Haemost. 2010;8(06):1424–1426.
    1. McCabe D J, Murphy S J, Starke Ret al.Relationship between ADAMTS13 activity, von Willebrand factor antigen levels and platelet function in the early and late phases after TIA or ischaemic stroke J Neurol Sci 2015348(1-2):35–40.
    1. Tobin W O, Kinsella J A, Kavanagh G F et al.Profile of von Willebrand factor antigen and von Willebrand factor propeptide in an overall TIA and ischaemic stroke population and amongst subtypes. J Neurol Sci. 2017;375:404–410.
    1. Andersson H M, Siegerink B, Luken B M et al.High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. Blood. 2012;119(06):1555–1560.
    1. Sonneveld M A, de Maat M P, Portegies M L et al.Low ADAMTS13 activity is associated with an increased risk of ischemic stroke. Blood. 2015;126(25):2739–2746.
    1. Smith F B, Lee A J, Fowkes F G, Price J F, Rumley A, Lowe G D. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol. 1997;17(11):3321–3325.
    1. Tzoulaki I, Murray G D, Lee A J, Rumley A, Lowe G D, Fowkes F G. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. Circulation. 2007;115(16):2119–2127.
    1. Bevan S, Traylor M, Adib-Samii P et al.Genetic heritability of ischemic stroke and the contribution of previously reported candidate gene and genomewide associations. Stroke. 2012;43(12):3161–3167.
    1. Traylor M, Farrall M, Holliday E G et al.Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol. 2012;11(11):951–962.
    1. Malik R, Traylor M, Pulit S L et al.Low-frequency and common genetic variation in ischemic stroke: the METASTROKE collaboration. Neurology. 2016;86(13):1217–1226.
    1. Auer P L, Nalls M, Meschia J F et al.Rare and coding region genetic variants associated with risk of ischemic stroke: the NHLBI Exome Sequence Project. JAMA Neurol. 2015;72(07):781–788.
    1. Network N SG; NINDS Stroke Genetics Network (SiGN); International Stroke Genetics Consortium (ISGC).Loci associated with ischaemic stroke and its subtypes (SiGN): a genome-wide association study Lancet Neurol 20161502174–184.
    1. Dichgans M, Malik R, König I R et al.Shared genetic susceptibility to ischemic stroke and coronary artery disease: a genome-wide analysis of common variants. Stroke. 2014;45(01):24–36.
    1. Van Schie M C, Wieberdink R G, Koudstaal P J et al.Genetic determinants of von Willebrand factor plasma levels and the risk of stroke: the Rotterdam Study. J Thromb Haemost. 2012;10(04):550–556.
    1. Fernández-Cadenas I, Del Río-Espínola A, Giralt D et al.IL1B and VWF variants are associated with fibrinolytic early recanalization in patients with ischemic stroke. Stroke. 2012;43(10):2659–2665.
    1. de Lange M, Snieder H, Ariëns R A, Spector T D, Grant P J.The genetics of haemostasis: a twin study Lancet 2001357(9250):101–105.
    1. Smith N L, Chen M H, Dehghan A et al.Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation. 2010;121(12):1382–1392.
    1. Huffman J E, de Vries P S, Morrison A C et al.Rare and low-frequency variants and their association with plasma levels of fibrinogen, FVII, FVIII, and vWF. Blood. 2015;126(11):e19–e29.
    1. van Loon J, Dehghan A, Weihong T et al.Genome-wide association studies identify genetic loci for low von Willebrand factor levels. Eur J Hum Genet. 2016;24(07):1035–1040.
    1. Antoni G, Oudot-Mellakh T, Dimitromanolakis A et al.Combined analysis of three genome-wide association studies on vWF and FVIII plasma levels. BMC Med Genet. 2011;12:102.
    1. van Schie M C, van Loon J E, de Maat M P, Leebeek F W. Genetic determinants of von Willebrand factor levels and activity in relation to the risk of cardiovascular disease: a review. J Thromb Haemost. 2011;9(05):899–908.
    1. Gallinaro L, Cattini M G, Sztukowska M et al.A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood. 2008;111(07):3540–3545.
    1. Millar C M, Brown S A. Oligosaccharide structures of von Willebrand factor and their potential role in von Willebrand disease. Blood Rev. 2006;20(02):83–92.
    1. Franchini M, Capra F, Targher G, Montagnana M, Lippi G. Relationship between ABO blood group and von Willebrand factor levels: from biology to clinical implications. Thromb J. 2007;5:14.
    1. Jenkins P V, O'Donnell J S. ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? Transfusion. 2006;46(10):1836–1844.
    1. Ozel A B, McGee B, Siemieniak D et al.Genome-wide studies of von Willebrand factor propeptide identify loci contributing to variation in propeptide levels and von Willebrand factor clearance. J Thromb Haemost. 2016;14(09):1888–1898.
    1. Desch K C, Ozel A B, Siemieniak D et al.Linkage analysis identifies a locus for plasma von Willebrand factor undetected by genome-wide association. Proc Natl Acad Sci U S A. 2013;110(02):588–593.
    1. Souto J C, Almasy L, Soria J M et al.Genome-wide linkage analysis of von Willebrand factor plasma levels: results from the GAIT project. Thromb Haemost. 2003;89(03):468–474.
    1. Keightley A M, Lam Y M, Brady J N, Cameron C L, Lillicrap D. Variation at the von Willebrand factor (vWF) gene locus is associated with plasma vWF:Ag levels: identification of three novel single nucleotide polymorphisms in the vWF gene promoter. Blood. 1999;93(12):4277–4283.
    1. van Schie M C, de Maat M P, Isaacs A et al.Variation in the von Willebrand factor gene is associated with von Willebrand factor levels and with the risk for cardiovascular disease. Blood. 2011;117(04):1393–1399.
    1. van Loon J E, Kavousi M, Leebeek F W et al.von Willebrand factor plasma levels, genetic variations and coronary heart disease in an older population. J Thromb Haemost. 2012;10(07):1262–1269.
    1. Campos M, Sun W, Yu F et al.Genetic determinants of plasma von Willebrand factor antigen levels: a target gene SNP and haplotype analysis of ARIC cohort. Blood. 2011;117(19):5224–5230.
    1. Suadicani P, Hein H O, Gyntelberg F. Airborne occupational exposure, ABO phenotype and risk of ischaemic heart disease in the Copenhagen Male Study. J Cardiovasc Risk. 2002;9(04):191–198.
    1. Marenberg M E, Risch N, Berkman L F, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med. 1994;330(15):1041–1046.
    1. Williams F M, Carter A M, Hysi P G et al.Ischemic stroke is associated with the ABO locus: the EuroCLOT study. Ann Neurol. 2013;73(01):16–31.
    1. Ay H, Gungor L, Arsava E M et al.A score to predict early risk of recurrence after ischemic stroke. Neurology. 2010;74(02):128–135.
    1. Arsava E M, Kim G M, Oliveira-Filho J et al.Prediction of early recurrence after acute ischemic stroke. JAMA Neurol. 2016;73(04):396–401.
    1. Sonneveld M A, van Dijk A C, van den Herik E G et al.Relationship of Von Willebrand Factor with carotid artery and aortic arch calcification in ischemic stroke patients. Atherosclerosis. 2013;230(02):210–215.
    1. Ohira T, Shahar E, Chambless L E, Rosamond W D, Mosley T H, Jr, Folsom A R. Risk factors for ischemic stroke subtypes: the Atherosclerosis Risk in Communities study. Stroke. 2006;37(10):2493–2498.
    1. Penz S M, Reininger A J, Toth O, Deckmyn H, Brandl R, Siess W. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques. Thromb Haemost. 2007;97(03):435–443.
    1. Hobl E L, Stimpfl T, Ebner J et al.Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2014;63(07):630–635.
    1. Spiel A O, Derhaschnig U, Schwameis M, Bartko J, Siller-Matula J M, Jilma B. Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a randomized controlled trial. Clin Sci (Lond) 2012;123(10):591–600.
    1. Derhaschnig U, Pachinger C, Jilma B. Variable inhibition of high-shear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: a randomized, placebo-controlled, clinical trial. Am Heart J. 2004;147(04):E17.
    1. Tobin W O, Kinsella J A, Kavanagh G F et al.Longitudinal assessment of von Willebrand factor antigen and von Willebrand factor propeptide in response to alteration of antiplatelet therapy after TIA or ischaemic stroke. J Neurol. 2014;261(07):1405–1412.
    1. Nilsson T K, Spence J D, Nilsson P M, Eliasson M, Jansson J H, Boman K. Quantitative measurement of carotid atherosclerosis in relation to levels of von Willebrand factor and fibrinolytic variables in plasma--a 2-year follow-up study. J Cardiovasc Risk. 2002;9(04):215–221.
    1. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.Tissue plasminogen activator for acute ischemic stroke N Engl J Med 1995333241581–1587.
    1. Hacke W, Kaste M, Bluhmki E et al.Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317–1329.
    1. Wardlaw J M, Murray V, Berge Eet al.Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis Lancet 2012379(9834):2364–2372.
    1. Powers W J, Derdeyn C P, Biller J et al.2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46(10):3020–3035.
    1. Kleindorfer D, Lindsell C J, Brass L, Koroshetz W, Broderick J P. National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke. 2008;39(03):924–928.
    1. Adeoye O, Hornung R, Khatri P, Kleindorfer D. Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years. Stroke. 2011;42(07):1952–1955.
    1. Wang Y, Liao X, Zhao X et al.Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China: analysis of the results from the Chinese National Stroke Registry (CNSR) Stroke. 2011;42(06):1658–1664.
    1. Barber P A, Zhang J, Demchuk A M, Hill M D, Buchan A M. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology. 2001;56(08):1015–1020.
    1. Cocho D, Belvís R, Martí-Fàbregas J et al.Reasons for exclusion from thrombolytic therapy following acute ischemic stroke. Neurology. 2005;64(04):719–720.
    1. O'Connor R E, McGraw P, Edelsohn L. Thrombolytic therapy for acute ischemic stroke: why the majority of patients remain ineligible for treatment. Ann Emerg Med. 1999;33(01):9–14.
    1. Nogueira R G, Jadhav A P, Haussen D C et al.Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018;378(01):11–21.
    1. Vivien D. Can the benefits of rtPA treatment for stroke be improved? Rev Neurol (Paris) 2017;173(09):566–571.
    1. Whiteley W N, Slot K B, Fernandes P, Sandercock P, Wardlaw J. Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies. Stroke. 2012;43(11):2904–2909.
    1. Montagne A, Hébert M, Jullienne A et al.Memantine improves safety of thrombolysis for stroke. Stroke. 2012;43(10):2774–2781.
    1. Yeo L L, Paliwal P, Teoh H L et al.Timing of recanalization after intravenous thrombolysis and functional outcomes after acute ischemic stroke. JAMA Neurol. 2013;70(03):353–358.
    1. Molina C A, Montaner J, Arenillas J F, Ribo M, Rubiera M, Alvarez-Sabín J. Differential pattern of tissue plasminogen activator-induced proximal middle cerebral artery recanalization among stroke subtypes. Stroke. 2004;35(02):486–490.
    1. Goyal M, Menon B K, van Zwam W Het al.Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials Lancet 2016387(10029):1723–1731.
    1. Singh B, Parsaik A K, Prokop L J, Mittal M K. Endovascular therapy for acute ischemic stroke: a systematic review and meta-analysis. Mayo Clin Proc. 2013;88(10):1056–1065.
    1. Sheth K N, Smith E E, Grau-Sepulveda M V, Kleindorfer D, Fonarow G C, Schwamm L H. Drip and ship thrombolytic therapy for acute ischemic stroke: use, temporal trends, and outcomes. Stroke. 2015;46(03):732–739.
    1. Zhao W, Che R, Shang S et al.Low-dose tirofiban improves functional outcome in acute ischemic stroke patients treated with endovascular thrombectomy. Stroke. 2017;48(12):3289–3294.
    1. O'Donnell M J, Chin S L, Rangarajan Set al.Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study Lancet 2016388(10046):761–775.
    1. Kernan W N, Ovbiagele B, Black H R et al.Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(07):2160–2236.
    1. Kamal A K, Naqvi I, Husain M R, Khealani B A. Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. Cochrane Database Syst Rev. 2011;(01):CD008076.
    1. Li X, Zhou G, Zhou X, Zhou S.The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials J Neurol Sci 2013332(1-2):92–96.
    1. Committee C S; CAPRIE Steering Committee.A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet 1996348(9038):1329–1339.
    1. Aldandashi S, Noor R, Wang C X, Uddin G, Shuaib A. Combination treatment with dipyridamole, aspirin, and tPA in an embolic model of stroke in rats. Exp Neurol. 2007;205(02):563–568.
    1. Lee J H, Park S Y, Lee W S, Hong K W. Lack of antiapoptotic effects of antiplatelet drug, aspirin and clopidogrel, and antioxidant, MCI-186, against focal ischemic brain damage in rats. Neurol Res. 2005;27(05):483–492.
    1. Sacco R L, Diener H C, Yusuf S et al.Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359(12):1238–1251.
    1. Rothwell P M, Algra A, Chen Z, Diener H C, Norrving B, Mehta Z.Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials Lancet 2016388(10042):365–375.
    1. Bath P M, Cotton D, Martin R H et al.Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis. Stroke. 2010;41(04):732–738.
    1. Zhang Q, Wang C, Zheng M et al.Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis. Cerebrovasc Dis. 2015;39(01):13–22.
    1. Diener H C, Bogousslavsky J, Brass L Met al.Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial Lancet 2004364(9431):331–337.
    1. Hilkens N A, Li L, Rothwell P M, Algra A, Greving J P. External validation of risk scores for major bleeding in a population-based cohort of transient ischemic attack and ischemic stroke patients. Stroke. 2018;49(03):601–606.
    1. Moake J L, Turner N A, Stathopoulos N A, Nolasco L, Hellums J D. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood. 1988;71(05):1366–1374.
    1. Rosafio F, Lelli N, Mimmi S et al.Platelet function testing in patients with acute ischemic stroke: an observational study. J Stroke Cerebrovasc Dis. 2017;26(08):1864–1873.
    1. Kunicki T J, Williams S A, Nugent D J et al.Lack of association between aspirin responsiveness and seven candidate gene haplotypes in patients with symptomatic vascular disease. Thromb Haemost. 2009;101(01):123–133.
    1. Wang Y, Zhao X, Lin J et al.Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA. 2016;316(01):70–78.
    1. Pan Y, Chen W, Xu Y et al.Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Circulation. 2017;135(01):21–33.
    1. Lin Y, Wang A, Li J et al. Impact of glycemic control on efficacy of clopidogrel in transient ischemic attack or minor stroke patients with CYP2C19 genetic variants . Stroke. 2017;48(04):998–1004.
    1. Li X, Ling L, Li C, Ma Q. Efficacy and safety of desmoteplase in acute ischemic stroke patients: a systematic review and meta-analysis. Medicine (Baltimore) 2017;96(18):e6667.
    1. Le Behot A, Gauberti M, Martinez De Lizarrondo S et al.GpIbα-VWF blockade restores vessel patency by dissolving platelet aggregates formed under very high shear rate in mice. Blood. 2014;123(21):3354–3363.
    1. Momi S, Tantucci M, Van Roy M, Ulrichts H, Ricci G, Gresele P. Reperfusion of cerebral artery thrombosis by the GPIb-VWF blockade with the Nanobody ALX-0081 reduces brain infarct size in guinea pigs. Blood. 2013;121(25):5088–5097.
    1. Denorme F, Langhauser F, Desender L et al.ADAMTS13-mediated thrombolysis of t-PA-resistant occlusions in ischemic stroke in mice. Blood. 2016;127(19):2337–2345.
    1. Fan M, Xu H, Wang L et al.Tissue plasminogen activator neurotoxicity is neutralized by recombinant ADAMTS 13. Sci Rep. 2016;6:25971.
    1. Gilbert J C, DeFeo-Fraulini T, Hutabarat R M et al.First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation. 2007;116(23):2678–2686.
    1. Knöbl P, Jilma B, Gilbert J C, Hutabarat R M, Wagner P G, Jilma-Stohlawetz P. Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura. Transfusion. 2009;49(10):2181–2185.
    1. Peyvandi F, Scully M, Kremer Hovinga J A et al.Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2016;374(06):511–522.
    1. Cataland S R, Peyvandi F, Mannucci P M et al.Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. Am J Hematol. 2012;87(04):430–432.
    1. Jilma B, Paulinska P, Jilma-Stohlawetz P, Gilbert J C, Hutabarat R, Knöbl P. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease. Thromb Haemost. 2010;104(03):563–570.
    1. Eikelboom J W, Connolly S J, Bosch J et al.Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319–1330.
    1. Johnston S C, Amarenco P, Albers G W et al.Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med. 2016;375(01):35–43.
    1. Amarenco P, Albers G W, Denison H et al.Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Lancet Neurol. 2017;16(04):301–310.
    1. Toyoda K.PRASTRO-1 Study – A Comparison of Prasugrel and Clopidogrel (Standard of Care);2017[Abstract]. Available at:. Accessed November 15, 2017
    1. Bonaca M P, Scirica B M, Braunwald E et al.New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 °P-TIMI 50 trial. J Am Coll Cardiol. 2014;64(22):2318–2326.
    1. Wang Y, Wang Y, Zhao X et al.Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369(01):11–19.
    1. Li Z, Wang Y, Zhao X et al.Treatment effect of clopidogrel plus aspirin within 12 hours of acute minor stroke or transient ischemic attack. J Am Heart Assoc. 2016;5(03):e003038.
    1. De Meyer S F, Schwarz T, Deckmyn H et al.Binding of von Willebrand factor to collagen and glycoprotein Ibalpha, but not to glycoprotein IIb/IIIa, contributes to ischemic stroke in mice--brief report. Arterioscler Thromb Vasc Biol. 2010;30(10):1949–1951.
    1. Van Bockstaele F, Holz J B, Revets H. The development of nanobodies for therapeutic applications. Curr Opin Investig Drugs. 2009;10(11):1212–1224.
    1. Ablynx announces positive topline results from the phase III hercules study of caplacizumab for the treatment of acquired TTP.2017
    1. Keefe A D, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov. 2010;9(07):537–550.
    1. Markus H S, McCollum C, Imray C, Goulder M A, Gilbert J, King A. The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized trial. Stroke. 2011;42(08):2149–2153.
    1. Jang I K, Gold H K, Ziskind A A et al.Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. Circulation. 1989;79(04):920–928.
    1. Tomkins A J, Schleicher N, Murtha L et al.Platelet rich clots are resistant to lysis by thrombolytic therapy in a rat model of embolic stroke. Exp Transl Stroke Med. 2015;7:2.
    1. Bustamante A L, Boada C, Penalba Aet al.ADAMTS13 Activity Predicts Response to Thrombolysis in the Acute Stroke SettingStroke Suppl2015
    1. Borggrefe J, Kottlors J, Mirza Met al.Differentiation of clot composition using conventional and dual-energy computed tomographyClin Neuroradiol2017
    1. Mazighi M, Tanasescu R, Ducrocq X et al.Prospective study of symptomatic atherothrombotic intracranial stenoses: the GESICA study. Neurology. 2006;66(08):1187–1191.
    1. Chimowitz M I, Lynn M J, Derdeyn C P et al.Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011;365(11):993–1003.
    1. Kasner S E, Chimowitz M I, Lynn M J et al.Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. Circulation. 2006;113(04):555–563.
    1. Zaidat O O, Fitzsimmons B F, Woodward B K et al.Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial. JAMA. 2015;313(12):1240–1248.
    1. Kim D, Lee S H, Joon Kim B et al.Secondary prevention by stroke subtype: a nationwide follow-up study in 46 108 patients after acute ischaemic stroke. Eur Heart J. 2013;34(35):2760–2767.
    1. Sonneveld M A, Kavousi M, Ikram M A et al.Low ADAMTS-13 activity and the risk of coronary heart disease - a prospective cohort study: the Rotterdam Study. J Thromb Haemost. 2016;14(11):2114–2120.
    1. Kageyama S, Yamamoto H, Yoshimoto R. Anti-human von willebrand factor monoclonal antibody AJvW-2 prevents thrombus deposition and neointima formation after balloon injury in guinea pigs. Arterioscler Thromb Vasc Biol. 2000;20(10):2303–2308.
    1. Zahger D, Fishbein M C, Garfinkel L I et al.VCL, an antagonist of the platelet GP1b receptor, markedly inhibits platelet adhesion and intimal thickening after balloon injury in the rat. Circulation. 1995;92(05):1269–1273.
    1. Yamashita A, Asada Y, Sugimura H et al.Contribution of von Willebrand factor to thrombus formation on neointima of rabbit stenotic iliac artery under high blood-flow velocity. Arterioscler Thromb Vasc Biol. 2003;23(06):1105–1110.
    1. Gandhi C, Khan M M, Lentz S R, Chauhan A K. ADAMTS13 reduces vascular inflammation and the development of early atherosclerosis in mice. Blood. 2012;119(10):2385–2391.
    1. Jin S Y, Tohyama J, Bauer R C, Cao N N, Rader D J, Zheng X L. Genetic ablation of Adamts13 gene dramatically accelerates the formation of early atherosclerosis in a murine model. Arterioscler Thromb Vasc Biol. 2012;32(08):1817–1823.
    1. LaMuraglia G M, Stoner M C, Brewster D C et al.Determinants of carotid endarterectomy anatomic durability: effects of serum lipids and lipid-lowering drugs. J Vasc Surg. 2005;41(05):762–768.
    1. Engelter S, Lyrer P. Antiplatelet therapy for preventing stroke and other vascular events after carotid endarterectomy. Cochrane Database Syst Rev. 2003;(03):CD001458.
    1. Matas M, Domínguez González J M, Montull E. Antiplatelet therapy in endovascular surgery: the RENDOVASC study. Ann Vasc Surg. 2013;27(02):168–177.
    1. Roubin G S, Yadav S, Iyer S S, Vitek J.Carotid stent-supported angioplasty: a neurovascular intervention to prevent stroke Am J Cardiol 199678(3A):8–12.
    1. Diethrich E B, Ndiaye M, Reid D B. Stenting in the carotid artery: initial experience in 110 patients. J Endovasc Surg. 1996;3(01):42–62.
    1. Bergeron P, Roux M, Khanoyan P, Douillez V, Bras J, Gay J. Long-term results of carotid stenting are competitive with surgery. J Vasc Surg. 2005;41(02):213–221.
    1. Kefer J M, Galanti L M, Desmet S, Deneys V, Hanet C E. Time course of release of inflammatory markers after coronary stenting: comparison between bare metal stent and sirolimus-eluting stent. Coron Artery Dis. 2005;16(08):505–509.
    1. Blann A, Midgley H, Burrows G et al.Free radicals, antioxidants, and endothelial cell damage after percutaneous transluminal coronary angioplasty. Coron Artery Dis. 1993;4(10):905–910.
    1. Robless P A, Tegos T J, Okonko D et al.Platelet activation during carotid endarterectomy and the antiplatelet effect of Dextran 40. Platelets. 2002;13(04):231–239.
    1. Yang H, Xu J X, Kong X Z et al.Relations between plasma von Willebrand factor or endothelin-1 and restenosis following carotid artery stenting. Med Princ Pract. 2012;21(06):538–542.
    1. Davis J A, Brown A T, Alshafie T et al.Saratin (an inhibitor of platelet-collagen interaction) decreases platelet aggregation and homocysteine-mediated postcarotid endarterectomy intimal hyperplasia in a dose-dependent manner. Am J Surg. 2004;188(06):778–785.
    1. Wang W, Jiang B, Sun H et al.Prevalence, incidence, and mortality of stroke in China: results from a nationwide population-based survey of 480 687 adults. Circulation. 2017;135(08):759–771.
    1. Niu J W, Gao S, Cui L Y et al.Intracranial atherosclerosis in Chinese young adult stroke patients. J Stroke Cerebrovasc Dis. 2014;23(06):1519–1523.
    1. Smith A, Patterson C, Yarnell J, Rumley A, Ben-Shlomo Y, Lowe G.Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study Circulation 2005112(20):3080–3087.
    1. Wieberdink R G, van Schie M C, Koudstaal P J et al.High von Willebrand factor levels increase the risk of stroke: the Rotterdam study. Stroke. 2010;41(10):2151–2156.
    1. Wannamethee S G, Whincup P H, Lennon L, Rumley A, Lowe G D. Fibrin D-dimer, tissue-type plasminogen activator, von Willebrand factor, and risk of incident stroke in older men. Stroke. 2012;43(05):1206–1211.
    1. Jilma-Stohlawetz P, Knöbl P, Gilbert J C, Jilma B. The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease. Thromb Haemost. 2012;108(02):284–290.
    1. Jilma-Stohlawetz P, Gorczyca M E, Jilma B, Siller-Matula J, Gilbert J C, Knöbl P. Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura. Thromb Haemost. 2011;105(03):545–552.
    1. Jilma-Stohlawetz P, Gilbert J C, Gorczyca M E, Knöbl P, Jilma B. A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura. Thromb Haemost. 2011;106(03):539–547.
    1. Machin S J, Clarke C, Ikemura O et al.A humanized monoclonal antibody against vWF A1 domain inhibits vWF:RiCof activity and platelet adhesion in human volunteers. J Thromb Haemost. 2003;1:Abstract OC328.
    1. Scully M, Knöbl P, Kentouche K et al.Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura. Blood. 2017;130(19):2055–2063.
    1. Hou Y, Reheman A, Li B X et al.Abstract 499: Development of a Novel Antithrombotic Therapy Targeting Platelet GPIbα: Assessment of Anfibatide In Vitro and in Phase I Clinical Trial. Arterioscler Thromb Vasc Biol. 2014;34 01:A499.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi